


gmendel[®]

**WE CARE
WE INNOVATE
WE COLLABORATE**

Building Tomorrow's
health care for
genetic disorders.



MedTech with a sea-change technology for diagnosis of genetic disorders for better disease management


Building tomorrow's
health care for
genetic disorders

- **Challenge:** 35OM + 7y + 40% = €2.5M/p + suffering
- **Competition:** 1) Biochemical: 63%; 2) NGS: months + €100
- **Our solution:** Genomics + AI + Blockchain = 99% + 24h + €10
- **Market:** €30B 2022 → €60B 2030
- **Pre-seed investment:** €3M = CE IVD + ISO13485 + IPR
- **Pre money valuation:** €15M
- **Seed round:** €2 m + €1M = 3 Dev Prod + 1 Com Prod
- **Round A:** €6 m = 4 Dev Prod + 2 Com Prod
- **Exit by 2027:** M&A Corporate investor



Key events 2022

Building tomorrow's health care for genetic disorders



Our Team & Ecosystem

Building tomorrow's
health care for
genetic disorders

"gMendel® appears to have the potential for a sea-change technology. My team and I were very impressed."

Head of a US state level
Department of Health

							
Chris Kyriakidis PhD, MSc, MBA <i>Co-founder</i>	Zoran Velkoski MSc, MBA <i>Co-founder</i>	Hanna Pyokari MSc <i>Co-founder</i>	Aleksandar Nikov BSc <i>Head of AI</i>	Carmen Navas Ph.D. MSc <i>Clinical Evaluation</i>	Tomasz Puk MBA, MSc <i>Head of Q&A</i>	Anne Schack MSc <i>Genomics Researcher</i>	Karmele Alapont MSc <i>Genomics Researcher</i>
							
Kristijan Jankoski MSc <i>Sr. Data Scientist</i>	David Galevski MSc <i>Data Scientist</i>	Marlja Chaushevskva MSc <i>AI Researcher</i>	Dariusz Nablaczyk MSc <i>Software Architect</i>	Agnieszka Tymoszyk BSc <i>Quality Assurance</i>	Dimitri Kyriakidis MSc <i>Advocacy & Sales Development</i>	Wouter Hamelink MSc <i>Advocacy & Sales Development</i>	Marla Andrieleou MSc <i>Marketing & Communications</i>

"a marvellous opportunity"

Health commissioner, US

Advisory Board & BoD

					
Zoran Zdraveski JD, PhD <i>Strategic Advisor</i>	Gjorgji Madjarov PhD, MSc <i>AI Advisor</i>	Lukasz Krych PhD, MSc <i>Genomics Advisor</i>	Ken Ndugga-Kabuye MD, BSc <i>US market Advisor</i>	Johan Leonhard LLM, Attorney <i>Legal Advisor</i>	Lars Staal Wegner MD <i>Chairman of BoD</i>



A poster child for innovation & profits when science meets patent lawyers meets venture capitalists

Building tomorrow's
health care for
genetic disorders

Genentech®

1978¹ | 2009² | 2020³

¹. Recombinant insulin; until then 1 kg of insulin required 8 tones of pancreas glands ripped from 50,000 pigs

². Valuation: \$106 B

³. Revenues: \$26.4 B

gMendel®

2022¹ | 2025² | 2027³

¹. 99% + 24h + €10

². Revenues: € 44 M

³. Valuation: € 234 M + Exit



gmendel®

